This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Hyperion Therapeutics Announces RAVICTI And BUPHENYL Pharmacokinetic Analyses Reported In The Journal Of Clinical Pharmacology

SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that population pharmacokinetic (PK) modeling and dosing simulations were reported in The Journal of Clinical Pharmacology based on data from four Phase 2 and 3 trials that collectively enrolled patients with urea cycle disorders (UCDs) ages 2 months to 72 years. The final model described the differences in absorption rate and pharmacokinetic profiles of the company's two drugs, RAVICTI® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, in patients with UCDs. The article is available through the Wiley online library ( http://onlinelibrary.wiley.com/doi/10.1002/jcph.92/abstract ).

UCDs represent a collection of inherited enzyme and transporter deficiencies that impair the synthesis of urea, the body's vehicle for waste nitrogen removal via the urine, which results in affected patients suffering from high systemic levels of ammonia, a potent neurotoxin. Since UCDs constitute an ultra-orphan population with an estimated U.S. patient pool of approximately 1000, population PK modeling and dosing simulations were performed to help define the clinical pharmacology of the two compounds as well as metabolite exposure in pediatric and adult UCD patients.

The final model helps explain differences in the level of plasma metabolites (drug breakdown products) during dosing of the two drugs based on differences in the amount of drug metabolized to phenylacetylglutamine prior to reaching the systemic circulation. Moreover, during dosing with RAVICTI as compared with BUPHENYL, phenylbutyric acid is absorbed 70-75% more slowly and blood metabolite levels generally show less fluctuation.

"These modeling data are particularly interesting in that the slower input of the active ingredient into the circulation with RAVICTI as compared with the bolus type drug release of BUPHENYL may allow for more sustained ammonia control," said Dr. George Diaz, Associate Professor, Department of Genetics & Genomic Sciences, Mount Sinai School of Medicine.

Stock quotes in this article: HPTX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,368.78 -56.07 -0.34%
S&P 500 1,861.27 -1.04 -0.06%
NASDAQ 4,083.6090 -2.6160 -0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs